Increased levels of circulating platelet-derived microparticles are associated with metastatic cutaneous melanoma

被引：6

作者：

Moreau, Josephine ^{[1
,2
]}

Pelletier, Fabien ^{[1
,2
]}

Biichle, Sabeha ^{[1
,3
]}

Mourey, Guillaume ^{[1
,3
]}

Puyraveau, Marc ^{[4
]}

Badet, Nicolas ^{[5
]}

Caubet, Matthieu ^{[6
]}

Laresche, Claire ^{[2
]}

Garnache-Ottou, Francine ^{[1
,3
]}

Saas, Philippe ^{[1
,3
]}

Seilles, Estelle ^{[1
,3
]}

Aubin, Francois ^{[1
,7
]}

机构：

[1] Univ Bourgogne Franche Comte, INSERM, UMR 1098, Besancon, France

[2] Univ Hosp, Dept Dermatol, Besancon, France

[3] Etab Francais Sang Bourgogne Franche Comte, Besancon, France

[4] Besancon Univ Hosp, Clin Methodol Ctr, Besancon, France

[5] Besancon Univ Hosp, Dept Radiol, Besancon, France

[6] Besancon Univ Hosp, Dept Radiotherapy, Besancon, France

[7] Univ Bourgogne Franche Comte, EA3181, Besancon, France

来源：

EXPERIMENTAL DERMATOLOGY | 2017年 / 26卷 / 10期

关键词：

melanoma; platelet-derived microparticles; platelets; thrombogenic activity; tumor burden; CANCER; CELLS;

D O I：

10.1111/exd.13339

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

We investigated the plasma levels of PMPs in patients with 45 stage III and 45 stage IV melanoma. PMPs were characterised by flow cytometry and their thrombogenic activity. We also investigated the link between PMPs circulating levels and tumor burden. The circulating levels of PMPs were significantly higher in stage IV (8500 mu L-1) than in patients with stage III (2041 mu L-1) melanoma (P=.0001). We calculated a highly specific (93.3%) and predictive (91.7%) cut-off value (5311 mu L-1) allowing the distinction between high-risk stage III and metastatic stage IV melanoma. The thrombogenic activity of PMPs was significantly higher in patients with stage IV melanoma (clotting time: 40.7second vs 65second, P=.0001). There was no significant association between the radiological tumoral syndrome and the plasma level of PMPs. Our data suggest the role of PMPs in metastatic progression of melanoma.

引用

页码：961 / 963

页数：3

共 8 条

[1] Membrane microvesicles: Macromessengers in cancer disease and progression
Castellana, Donatello
Toti, Florence
Freyssinet, Jean-Marie
[J]. THROMBOSIS RESEARCH, 2010, 125 : S84 - S88
[2] Platelet microparticles and cancer: An intimate cross-talk
Goubran, Hadi
Sabry, Waleed
Kotb, Rami
Seghatchian, Jerard
Burnouf, Thierry
[J]. TRANSFUSION AND APHERESIS SCIENCE, 2015, 53 (02) : 168 - 172
[3] Platelet Interaction with Innate Immune Cells
Kral, Julia Barbara
Schrottmaier, Waltraud Cornelia
Salzmann, Manuel
Assinger, Alice
[J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2016, 43 (02) : 78 - 88
[4] Increased Levels of Circulating Microparticles Are Associated with Increased Procoagulant Activity in Patients with Cutaneous Malignant Melanoma
Laresche, Claire
Pelletier, Fabien
Garnache-Ottou, Francine
Lihoreau, Thomas
Biichle, Sabeha
Mourey, Guillaume
Saas, Philippe
Humbert, Philippe
Seilles, Estelle
Aubin, Francois
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (01) : 176 - 182
[5] Nomura Shosaku, 2015, Biomark Cancer, V7, P51, DOI 10.4137/BIC.S30347
[6] Cancer and venous thromboembolism
Prandoni, P
Falanga, A
Piccioli, A
[J]. LANCET ONCOLOGY, 2005, 6 (06) : 401 - 410
[7] Microparticle-mediated transfer of TF hypercoagulability between cancer cells
Shaker, H.
Rothmeier, A. S.
Kirwan, C. C.
Ruf, W.
[J]. THROMBOSIS RESEARCH, 2016, 140 : S172 - S172
[8] Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia
Willms, Arnulf
Mueller, Clara
Julich, Henrike
Klein, Niklas
Schwab, Robert
Guesgen, Christoph
Richardsen, Ines
Schaaf, Sebastian
Krawczyk, Marcin
Krawczyk, Marek
Lammert, Frank
Schuppan, Detlef
Lukacs-Kornek, Veronika
Kornek, Miroslaw
[J]. ONCOTARGET, 2016, 7 (21) : 30867 - 30875

← 1 →